Literature DB >> 15049807

Molecular architecture of the Cryptococcus neoformans capsule.

Marcellene A Gates1, Peter Thorkildson, Thomas R Kozel.   

Abstract

Many microbes are surrounded by phagocytosis-inhibiting capsules. We took advantage of the large size of the polysaccharide capsule of the pathogenic yeast Cryptococcus neoformans to examine capsular architecture and the relationship between molecular architecture and the interaction of the capsule with potentially opsonic serum proteins. Our experimental design used complementary approaches in which (i) assessment of permeability to macromolecules of different Stokes radii; (ii) determination of the binding of Fab fragments of anticapsular antibodies as a measure of matrix density; (iii) capsular deconstruction by treatment with dimethyl sulphoxide; and (iv) evaluation of capsule plasticity, were used to probe the molecular structure of the capsule. The results showed that the capsule is a matrix with a variable porosity that increases with distance from the cell wall. A high density of the matrix at the capsule interior prevents penetration of large macromolecules to sites near the cell wall. In contrast, the capsular edge that is the interface with phagocytes presents capsular polysaccharide in a very low density that exhibits considerable plasticity and permeability to macromolecules. Notably, the capsule of yeast cells harvested from infected tissue showed a greater matrix density than yeast cells grown in vitro under capsule induction conditions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15049807     DOI: 10.1111/j.1365-2958.2003.03957.x

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  64 in total

Review 1.  Role of phagocytosis in the virulence of Cryptococcus neoformans.

Authors:  Maurizio Del Poeta
Journal:  Eukaryot Cell       Date:  2004-10

2.  Capsule Prolongs Survival of Streptococcus pneumoniae during Starvation.

Authors:  Shigeto Hamaguchi; M Ammar Zafar; Michael Cammer; Jeffrey N Weiser
Journal:  Infect Immun       Date:  2018-02-20       Impact factor: 3.441

3.  Radial mass density, charge, and epitope distribution in the Cryptococcus neoformans capsule.

Authors:  Michelle E Maxson; Ekaterina Dadachova; Arturo Casadevall; Oscar Zaragoza
Journal:  Eukaryot Cell       Date:  2006-11-17

4.  Characterization of a flocculation-like phenotype in Cryptococcus neoformans and its effects on pathogenesis.

Authors:  Li Li; Oscar Zaragoza; Arturo Casadevall; Bettina C Fries
Journal:  Cell Microbiol       Date:  2006-06-07       Impact factor: 3.715

5.  Differential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans.

Authors:  Marcellene A Gates; Thomas R Kozel
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

6.  Of mice and men, revisited: new insights into an ancient molecule from studies of complement activation by Cryptococcus neoformans.

Authors:  Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

7.  CPS1, a homolog of the Streptococcus pneumoniae type 3 polysaccharide synthase gene, is important for the pathobiology of Cryptococcus neoformans.

Authors:  Y C Chang; A Jong; S Huang; P Zerfas; K J Kwon-Chung
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

8.  Regulation of Cryptococcus neoformans capsule size is mediated at the polymer level.

Authors:  Aki Yoneda; Tamara L Doering
Journal:  Eukaryot Cell       Date:  2007-12-21

9.  Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations.

Authors:  Leonardo Nimrichter; Susana Frases; Leonardo P Cinelli; Nathan B Viana; Antonio Nakouzi; Luiz R Travassos; Arturo Casadevall; Marcio L Rodrigues
Journal:  Eukaryot Cell       Date:  2007-06-15

10.  Size Matters: Measurement of Capsule Diameter in Cryptococcus neoformans.

Authors:  Tiffany Guess; Hoyin Lai; Serenah E Smith; Linda Sircy; Kirsten Cunningham; David E Nelson; Erin E McClelland
Journal:  J Vis Exp       Date:  2018-02-27       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.